UPDATE : Monday, September 7, 2020
상단여백
‘Korea should lead precision medicine -- now’
Precision medicine has emerged as a new hope for cancer patients who have n...
by Nam Doo-hyun  |  2017-11-06 06:00
라인
Celltrion’s US sales of Remsima up 48% in Q3
Celltrion’s Remsima (ingredient: infliximab), a therapy to treat autoimmune...
by Nam Doo-hyun  |  2017-11-01 15:51
라인
‘Government’s undue intervention hinders growth of CROs’
The government’s excessive intervention in the biopharmaceutical service ma...
by Nam Doo-hyun  |  2017-10-27 17:35
라인
‘Early diagnosis more important than immunotherapy to cure lung cancer’
The Korean Association for Lung Cancer (KALC) has set about to emphasize th...
by Nam Doo-hyun  |  2017-10-25 15:22
라인
Will induced pluripotent stem cells avoid ethical issues?
Stem cell researchers and related industry officials are paying attention t...
by Nam Doo-hyun  |  2017-10-17 15:25
라인
Stem cell treatment for diabetes nears
Korean diabetes patients might have come one step closer to getting a stem ...
by Nam Doo-hyun  |  2017-10-13 15:47
라인
Celltrion rises high in Korean stock market
South Korean biopharmaceutical firm Celltrion’s shares rose high in the loc...
by Nam Doo-hyun  |  2017-10-11 16:11
라인
KDA unveils new guidelines on antidiabetic therapy
The Korean Diabetes Association unveiled its latest guidelines for diabetes...
by Nam Doo-hyun  |  2017-09-29 15:35
라인
‘Short disposable syringe increases insulin treatment effect’
A disposable short injection syringe is effective in insulin treatment, an ...
by Nam Doo-hyun  |  2017-09-29 10:30
라인
Korean drugmakers’ smart factories at ‘base level’
An increasing number of Korean pharmaceutical firms have built smart factor...
by Nam Doo-hyun  |  2017-09-28 16:00
라인
Drugmakers need to differentiate big data from ‘large data’
It is necessary for Korean pharmaceutical companies to distinguish big data...
by Nam Doo-hyun  |  2017-09-27 17:44
라인
Can Celltrion, Samsung make stable earnings with biosimilar?
Amid the intensifying competition to lower drug prices, market watchers pre...
by Nam Doo-hyun  |  2017-09-26 17:31
라인
‘Keytruda will beat Opdivo in US because of biomarker’
"Opdivo had gone ahead of Keytruda in America until last year, but Keytruda...
by Nam Doo-hyun  |  2017-09-26 15:57
라인
With rival out, expectations growing on Genexine
With its main rival out of the race to develop sustained growth hormone the...
by Nam Doo-hyun  |  2017-09-25 13:52
라인
State agency points to gender gap in medical research
Female researchers who majored in medicine and public health and took the l...
by Nam Doo-hyun  |  2017-09-21 17:13
라인
Korea lags far behind in biomedical R&D: report
Korea’s investment in the biomedical research and development lags far behi...
by Nam Doo-hyun  |  2017-09-21 16:14
라인
Combination vaccines expand range of prevention
Combination vaccines, which can prevent more viruses with fewer injections,...
by Nam Doo-hyun  |  2017-09-21 15:23
라인
Sillajen emerges as biggest beneficiary of preferential listing
Sillajen has emerged as the most successful case of the preferential listin...
by Nam Doo-hyun  |  2017-09-20 17:22
라인
Technology transfer to Genexine imminent
Genexine, which had brought anxiety to investors because of sudden stepdown...
by Nam Doo-hyun  |  2017-09-19 18:02
라인
Pharmaceutical industry leading new growth in Korea: report
The pharmaceutical industry is leading technological innovation and knowled...
by Nam Doo-hyun  |  2017-09-18 14:50
-이전1112131415161718-
176 civic groups furious over government-doctors deal176 civic groups furious over government-doctors deal
여백
Most viewed
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top